



Cover image: Co-localisation of P140 and HSC70 on spleen sections from MRL/lpr mice that received intravenously 200 µg rhodamine-labelled P140. See p 840.

Editor

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 8.11

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2011 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission ARD is published by BMJ Publishing Group Ltd typeset by Newgen and printed in the UK on acid-free paper from sustainable forests by Latimer Trend, Plymouth

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Mercury International Ltd. Periodicals postage paid at Rahway, NJ, USA. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases* Mercury International Ltd, 365 Blair Road, Avenel NJ 07001, USA.

Editorial

- 717** Joint space narrowing, cartilage and physical function: are we deceived by measurements and distributions?
R Landewé, D van der Heijde

Viewpoint

- 719** Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment
C S Crowson, S E Gabriel

Recommendation

- 722** European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects
M P T de Wit, S E Berlo, G J Aanerud, D Aletaha, J W Bijlsma, L Croucher, J A P Da Silva, B Clüsing, L Gossec, S Hewlett, M Jongkees, D Magnusson, M Scholte-Voshaar, P Richards, C Ziegler, T A Abma

Review

- 727** Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes
A Hot, P Miossec

Clinical and epidemiological research

- 733** Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction
D Aletaha, J Funovits, J S Smolen
- 740** Validation of a numerical rating scale to assess functional impairment in hip and knee osteoarthritis: comparison with the WOMAC function scale
P Ornetti, M Dougados, S Paternotte, I Logeart, L Gossec
- 747** A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)
P Quartier, F Allantaz, R Cimaz, P Pillet, C Messiaen, C Bardin, X Bossuyt, A Boutten, J Bienvu, A Duquesne, O Richer, D Chaussabel, A Mogenet, J Banchereau, J-M Treluyer, P Landais, V Pascual

- 755** Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
G R Burmester, E Feist, H Kellner, J Braun, C Iking-Konert, A Rubbert-Roth

- 760** Lupus Atherosclerosis Prevention Study (LAPS)
M A Petri, A N Kiani, W Post, L Christopher-Stine, L S Magder

- 766** Cardiac dysfunction in juvenile dermatomyositis: a case-control study
T Schwartz, H Sanner, T Husebye, B Flato, I Sjaastad

- 772** Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase
M G H van de Sande, M J H de Hair, C van der Leij, P L Klarenbeek, W H Bos, M D Smith, M Maas, N de Vries, D van Schaardenburg, B A C Dijkmans, D M Gerlag, P P Tak

- 778** Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial
C C Mok, K Y Ying, C H To, L Yim Ho, K L Yu, H K Lee, K M Ma

- 785** High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
K Au, G Reed, J R Curtis, J M Kremer, J D Greenberg, V Strand, D E Furst; on behalf of the CORRONA Investigators

- 792** Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments
B Saleem, A K Brown, H Keen, S Nizam, J Freeston, R Wakefield, Z Kanm, M Quinn, E Hensor, P G Conaghan, P Emery

- 799** Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)
M Dougados, J Braun, S Szanto, B Combe, M Elbaz, P Geher, G Thabut, V Leblanc, I Logeart

- 805** Assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST study
A Guermazi, F W Roemer, D Hayashi, M D Crema, J Niu, Y Zhang, M D Marra, A Katur, J A Lynch, G Y El-Khoury, K Baker, L B Hughes, M C Nevitt, D T Felson

- 812** Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study
S A Provan, A G Semb, J Hisdal, E Strandén, S Agewall, H Dagfinrud, K Angel, D Atar, T K Kvien

- 818** The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel
G Burmester, A Lanas, L Biasucci, M Hermann, S Lohmander, I Olivieri, C Scarpignato, J Smolen, C Hawkey, A Bajkowskai, F Berenbaum, F Breedveld, P Dieleman, M Dougados, T MacDonald, E M Mola, T Mets, N V D Noortgate, H Soevelaar

MORE CONTENTS ►



This article has been chosen by the editor to be of special interest or importance and is freely available online.



Articles carrying the Unlocked Logo are freely available online under the BMJ Journals unlocked scheme. See <http://ard.bmj.com/info/unlocked.dtl>



COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk



When you have finished with this please recycle it

- 823** Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register
S M M Verstappen, Y King, K D Watson, D P M Symmons, K L Hyrich; BSRBR Control Centre Consortium, BSR Biologics Register

- 827** A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program
S Muñoz-Fernández, L Carmona, E Collantes, J Mulero, M J García-Yébenes, E de Miguel, R Almodovar, C Fernández-Carballido, J F G Llorente, M Gobbo, the Esperanza Group

Basic and translational research

- 831** Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis
A P Liao, M Salajegheh, R Nazareno, J C Kagan, R G Jubin, S A Greenberg

- 837** HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus
N Page, F Gros, N Schall, M Décossas, D Bagnard, J-P Briand, S Muller

- 844** Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice
C J Wruck, A Fragoulis, A Gurzynski, L-O Brandenburg, Y W Kan, K Chan, J Hassenpflug, S Freitag-Wolf, D Varoga, S Lippross, T Pufe

- 851** The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype
I R Klein-Wieringa, M Kloppenburg, Y M Bastiaansen-Jenniskens, E Yusuf, J C Kwekkeboom, H El-Bannoudi, R G H H Nelissen, A Zuurmond, V Stojanovic-Susulic, G J V M Van Osch, R E M Toes, A Ioan-Facsinay

- 858** Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis
M Corr, D L Boyle, L M Ronacher, B R Lew, L G van Baarsen, P P Tak, G S Firestein

- 864** Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study
K Panoutsopoulou, L Southam, K S Elliott, N Wrayner, G Zhai, C Beazley, G Thorleifsson, N K Arden, A Carr, K Chapman, P Deloukas, M Doherty, A McCaskie, W E R Ollier, S H Ralston, T D Spector, A M Valdes, G A Wallis, J M Wilkinson, E Arden, K Battley, H Blackburn, F J Blanco, S Bumpstead, L A Cupples, A G Day-Williams, K Dixon, S A Doherty, T Esko, E Evangelou, D Felson, J J Gomez-Reino, A Gonzalez, A Gordon, R Gwilliam, B V Halldorsson, V B Hauksson, A Hofman, S E Hunt, J P A Ioannidis, T Ingvarsson, I Jonsdottir, H Jonsson, R Keen, H J M Kerkhof, M G Kloppenburg, N Koller, N Lakenberg, N E Lane, A T Lee, A Metspalu, I Meulenbelt, M C Nevitt, F O'Neill, N Parimi, S C Potter, I Rego-Perez, J A Riancho, K Sherburn, P E Slagboom, K Stefansson, U Styrcarsdottir, M Sumillera, D Swift, U Thorsteinsdottir, A Tsezou, A G Uitterlinden, J B J van Meurs, B Watkins, M Wheeler, S Mitchell, Y Zhu, J M Zmuda; arcOGEN Consortium, E Zeggini, J Loughlin

- 868** Expansion of myelin autoreactive CD8+ T lymphocytes in patients with neuropsychiatric systemic lupus erythematosus
C Contin-Bordes, E Lazaro, C Richez, C Jacquemin, O Caubet, I Douchet, J-F Viillard, J-F Moreau, J-L Pellegrin, P Blanco

Letters

- 872** Sleep problems are of higher priority for improvement for patients with ankylosing spondylitis than for patients with other inflammatory arthropathies
T Heiberg, E Lie, D van der Heijde, T K Kvien

- 873** The *GDF5* rs143383 polymorphism is associated with osteoarthritis of the knee with genome-wide statistical significance
A M Valdes, E Evangelou, H J M Kerkhof, A Tamm, S A Doherty, K Kisand, A Tamm, I Kema, A Uitterlinden, A Hofman, F Rivadeneira, C Cooper, E M Dennison, W Zhang, K R Muir, J P A Ioannidis, M Wheeler, R A Maciewicz, J B van Meurs, N K Arden, T D Spector, M Doherty

- 875** Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis
A Jannitski, I M Visman, M J L Peters, M Boers, B A C Dijkemans, M T Nurmohamed

- 877** Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
E E A Arts, T L Jansen, A Den Broeder, H E Vonckenman, E Dutmer, M A F J Van de Laar, P L C M Van Riel, J Fransen

- 879** Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis
P Król, O Kryšůňková, M Polanská, H Mann, M Klein, O Beran, J Vencovský

Miscellaneous

- 880** Corrections